Page 6 - Commodore Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials

United statesChristi waarichAndrew robbinsExchange commissionCogent biosciences incAmerican academy of asthmaRedmile groupPiper sandler coJp morgan securitiesCogent research teamCogent biosciencesCommodore capitalFairmount fundsAdage capital partnersVenrock healthcare capital partnersPiper sandler

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst (COGT)

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst (COGT)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPiper sandler coJp morgan securitiesCogent biosciences incAmerican academy of allergyRedmile groupDrug agencyText big newsCommodore capitalFairmount fundsAdage capital partnersVenrock healthcare capital partnersPiper sandlerHealthcare conferenceSystemic mastocytosis

Cabaletta Bio, Inc (NASDAQ:CABA) Given Average Recommendation of Buy by Brokerages

Cabaletta Bio, Inc (NASDAQ:CABA) Given Average Recommendation of Buy by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Gwendolyn binderStifel nicolausWilliam blairBain capital life sciences investorsBlackrock incCabaletta bio company profileCantor fitzgeraldFred alger managementJefferies financial groupSecurities exchange commissionCabaletta bio incPerceptive advisorsCabaletta bioGet free reportFinancial groupExchange commission

Brokerages Set IDEAYA Biosciences, Inc (NASDAQ:IDYA) PT at $36 73

Brokerages Set IDEAYA Biosciences, Inc (NASDAQ:IDYA) PT at $36 73
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesBriseno andres ruizDekabank deutsche girozentraleYujiros hataTd asset management incBiosciences incRoyal bankGoldman sachs groupSecurities exchange commissionAmerican international group incJpmorgan chase coZiegler capital managementGet free reportMarketbeat ratingsStock downExchange commission

Vaxcyte (NASDAQ:PCVX) Reaches New 12-Month High at $66 48

Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $66.48 and last traded at $66.41, with a volume of 180384 shares traded. The stock had previously closed at $64.31. Analyst Ratings Changes A number of analysts recently commented on […]

United statesMikhail eydelmanCantor fitzgeraldVaxcyte incGroupa streptococcusFred alger managementSecurities exchange commissionNeedham companyBlackrock incWestfield capital management coGet free reportExchange commissionCapital managementAlger managementCommodore capitalVaxcyte daily